Collaborations

The company has its own drug development agenda focusing on protein targets involved in cancer and inflammatory diseases (e.g., mitogen-activated protein kinases) but it is also eager to enter into collaborations with drug developers on other protein targets (e.g., based on a fee-for-service model or on a collaborative research agreement to seek forward IP jointly).